Synaptogenix Inc SNPX Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 29, 2023 (filed on Mar 31, 2023)

Insider Name:

Schechter Jonathan

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Mar 29, 2023 (filed on Mar 31, 2023)

Insider Name:

Singer William S.

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Mar 29, 2023 (filed on Mar 31, 2023)

Insider Name:

Bernstein Bruce

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Mar 29, 2023 (filed on Mar 31, 2023)

Insider Name:

Silverman Joshua

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Singer William S.

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-27,000

Price:

$1.17
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Weinstein Robert

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-27,000

Price:

$1.17
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Silverman Joshua

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-19,012

Price:

$1.17
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Schechter Jonathan

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-20,250

Price:

$1.17
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Alkon Daniel L.

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-19,688

Price:

$1.17
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Bernstein Bruce

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-22,500

Price:

$1.17

Filings by filing date

Mar 29, 2023 (filed on Mar 31, 2023)

Insider Name:

Schechter Jonathan

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Mar 29, 2023 (filed on Mar 31, 2023)

Insider Name:

Singer William S.

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Mar 29, 2023 (filed on Mar 31, 2023)

Insider Name:

Bernstein Bruce

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Mar 29, 2023 (filed on Mar 31, 2023)

Insider Name:

Silverman Joshua

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Singer William S.

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-27,000

Price:

$1.17
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Weinstein Robert

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-27,000

Price:

$1.17
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Silverman Joshua

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-19,012

Price:

$1.17
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Schechter Jonathan

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-20,250

Price:

$1.17
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Alkon Daniel L.

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-19,688

Price:

$1.17
Dec 16, 2022 (filed on Dec 20, 2022)

Insider Name:

Bernstein Bruce

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001 per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-22,500

Price:

$1.17

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036
Tel:	N/A
Website:	https://www.synaptogen.com
IR:	See website

Key People

Daniel L. Alkon President, Chief Scientific Officer, Director	Alan J. Tuchman Chief Executive Officer, Director	William S. Singer Independent Vice Chairman of the Board
Robert Weinstein Chief Financial Officer, Executive Vice President, Treasurer, Secretary

Business Overview

Synaptogenix, Inc. is a biopharmaceutical company. The Company is principally focused on developing therapeutics for patients with neurodegenerative diseases and developmental disorders. The Company is focused on developing a product platform based on a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer's disease (AD). Bryostatin-1 is a Protein Kinase C Epsilon (PKC e), a and e activator that was originally developed as a potential anticancer drug. The Company is evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease.

Financial Overview

For the three months ended 31 March 2023, Synaptogenix Inc revenues was not reported. Net loss applicable to common stockholders decreased 40% to $2M. Lower net loss reflects Research and development - Balancing decrease of 43% to $778K (expense), Interest Income increase from $5K to $396K (income), Stock-based Compensation in SGA decrease of 8% to $545K (expense).

Employees:	5 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	N/A
Annual revenue (TTM):	$0.00M as of Mar 31, 2023
EBITDA (TTM):	-$15.77M as of Mar 31, 2023
Net annual income (TTM):	-$4.39M as of Mar 31, 2023
Free cash flow (TTM):	-$9.43M as of Mar 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	7,359,871 as of May 10, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization